Phase I Study to Evaluate the Safety, Tolerability, and Pharmacodynamics (PD) of DWRX2003 (Niclosamide IM Depot) Injection Following Intramuscular Administration in COVID-19 Patients
Latest Information Update: 28 Sep 2021
At a glance
- Drugs Niclosamide (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors Daewoong Pharmaceutical
- 16 Sep 2021 Status changed from not yet recruiting to discontinued. (Enrolment was suspended since 09Dec2020 due to a lack of COVID-19 patients.)
- 10 Sep 2020 New trial record
- 07 Sep 2020 According to a Daewoong Pharmaceutical media release, the Food and Drug Administration (FDA) of the Philippines has approved for this study. The study will begin in Sep 2020.